Grail (NASDAQ:GRAL) versus Enzo Biochem (NYSE:ENZ) Critical Review

Grail (NASDAQ:GRAL) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional & Insider Ownership

36.9% of Enzo Biochem shares are owned by institutional investors. 11.4% of Enzo Biochem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Grail and Enzo Biochem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grail	N/A	N/A	N/A
Enzo Biochem	-81.73%	-11.84%	-8.31%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Grail and Enzo Biochem, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grail	0	3	0	0	2.00
Enzo Biochem	0	0	0	0	0.00

Grail currently has a consensus price target of $16.00, suggesting a potential downside of 10.46%. Given Grail’s stronger consensus rating and higher probable upside, analysts plainly believe Grail is more favorable than Enzo Biochem.

Earnings and Valuation

This table compares Grail and Enzo Biochem”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grail	$117.67 million	5.10	N/A	N/A	N/A
Enzo Biochem	$30.31 million	1.21	-$26.08 million	N/A	N/A

Grail has higher revenue and earnings than Enzo Biochem.

Summary

Grail beats Enzo Biochem on 7 of the 9 factors compared between the two stocks.

About Grail

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

About Enzo Biochem

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.